sponsored
PatientsVille.com Logo

PatientsVille

Influenza Medical Research Studies

Up-to-date List of Influenza Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Influenza Medical Research Studies

Rank Status Study
1 Recruiting Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Conditions: Cancer;   Influenza Viral Infections
Interventions: Biological: Standard Trivalent Influenza Vaccine;   Biological: High-Dose Influenza Vaccine
Outcome Measures: The Geometric Mean Titer (GMT) of high-dose Influenza vaccine vs the standard trivalent Influenza vaccine in adult subjects on chemotherapy who are less than 65 years old.;   The seroprotection rate of high-dose Influenza vaccine vs standard trivalent Influenza vaccine in adult subjects on chemotherapy less than 65 years old.;   The seroconversion rate of high-dose Influenza vaccine versus standard trivalent Influenza vaccine in adult subjects on chemotherapy less than 65 years old.;   Evaluate and compare the local and systemic adverse events to both vaccines.
2 Recruiting Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Condition: Influenza
Interventions: Biological: High Dose Inactivated Influenza Vaccine;   Biological: Standard Dose Inactivated Influenza Vaccine
Outcome Measures: Non-inferiority of high-dose inactivated Influenza vaccine(HDIV) versus standard dose inactivated Influenza vaccine(SDIV) among residents of long term care(LTC) settings;   Non-inferiority and immunoprotection persistence at 6 months and the impact of potential immune modulators on titer response
3 Recruiting Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Condition: Influenza Virus
Interventions: Biological: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV);   Biological: Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Outcome Measures: RT-PCR-confirmed Influenza cases in all subjects;   Percentage of subjects with solicited AEs;   Percentage of subjects with all unsolicited AEs;   Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, new onset of chronic disease, Adverse Event of Special Interest (AESI) and all medications associated;   Hazard ratios calculated: Occurrence of RT-PCR and culture-confirmed Influenza cases in all subjects;   Hazard ratios calculated: Early occurrence of RT-PCR-confirmed Influenza cases in all subjects;   Geometric mean HI titer (GMT);   Geometric mean ratio (GMR);   Percentage of vaccine naïve and non-naïve subjects achieving seroconversion;   Percentage of subjects with HI titer ≥ 1:40;   Percentage of subjects with higher HI titer thresholds;   Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, New Onset of Chronic Disease (NOCD), Adverse Events of Special Interest(AESI) and all medications associated
4 Recruiting Evaluate Reactogenicity and Immunogenicity of Standard-dose (SD) Versus High-dose (HD) Inactivated Influenza Vaccine Trivalent (IIV3) in Recipients of Solid Organ Transplants.
Conditions: Influenza, Human;   Transplantation Infection
Interventions: Biological: Influenza trivalent inactive vaccine;   Biological: Influenza trivalent inactive vaccine high dose
Outcome Measures: Number of patients with local or systemic reactions;   Measurement of strain-specific hemagglutination inhibition (HI) antibody titers;   All cause hospitalization;   All cause ED visits/unscheduled clinic visits;   Evaluate seroconversion and seroprotection rates
5 Unknown  FluMist in Egg Allergic Patients
Conditions: Egg Allergy;   Eligible for Vaccination Against Influenza
Interventions: Biological: FluMist intranasal Influenza vaccine;   Biological: Intramuscular Influenza injection ("flu shot")
Outcome Measures: To estimate the safety of LAIV in egg-allergic patients receiving the LAIV.;   To estimate the safety of a single, full-strength dose of TIV in egg allergic patients.
6 Unknown  Seasonal Influenza Vaccine Effectiveness Study in Kenya
Conditions: Influenza;   Influenza Like Illness;   Severe Acute Respiratory Illness
Intervention: Biological: Seasonal Influenza vaccine
Outcome Measures: Laboratory-confirmed Influenza infection;   Medically attended Influenza Like Illness(ILI) and Severe Acute Respiratory Illness (SARI);   Community-reported ILI SARI;   Laboratory-confirmed Influenza, medically attended ILI and SARI, and community-reported ILI and SARI in non-immunized household members
7 Recruiting The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis
Conditions: Immunogenicity and Adverse Drug Effect of Vaccines Influenza;   Chronic Kidney Disease
Intervention: Biological: Seasonal Influenza vaccine (AdimFlu-S)
Outcome Measures: The dynamic change of seroprotection rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.;   The safety of the Influenza vaccination in patients with chronic kidney disease.;   The dynamic change of seroconversion rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.;   The dynamic change of seroresponse rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.
8 Unknown  Two-site Intradermal Influenza Vaccination in Elderly
Condition: Influenza
Intervention: Biological: seasonal Influenza vaccine
Outcome Measures: immunogenicity;   comparison of the immunogenicity;   safety
9 Recruiting An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Condition: Influenza
Interventions: Biological: Influenza vaccine GSK2321138A;   Biological: Havrix Junior;   Biological: Prevenar 13;   Biological: Varivax/ProVarivax;   Biological: Varilrix
Outcome Measures: First occurrence of Reverse transcription polymerase chain reaction (RT-PCR) confirmed moderate to severe Influenza A and/or B disease due to any seasonal Influenza strain;   First occurrence of RT-PCR confirmed Influenza A and/or B disease of any severity due to any seasonal Influenza strain;   First occurrence of Lower respiratory illness (LRI) with RT-PCR confirmed Influenza A and/or B infection due to any seasonal Influenza strain identified at any time starting 7 days before the onset of LRI and ending 7 days after end of LRI;   First occurrence of culture-confirmed moderate to severe Influenza A and/or B disease due to antigenically-matching Influenza strains;   First occurrence of culture-confirmed Influenza A and/or B disease of any severity due to antigenically-matching Influenza strains;   First occurrence of culture-confirmed moderate to severe Influenza A and/or B disease due to any seasonal Influenza strain;   First occurrence of culture-confirmed Influenza A and/or B disease of any severity due to any seasonal Influenza strain;   First occurrence of acute otitis media (AOM) with RT-PCR confirmed Influenza A and/or B infection due to any seasonal Influenza strain identified at any time starting 7 days before the onset of AOM and ending 7 days after end of AOM;   First occurrence of RT-PCR confirmed severe Influenza A and/or B due to any seasonal Influenza strain;   Humoral immune response in terms of haemagglutination-inhibition (HI) antibody titres against each of four vaccine strains contained in the FLU D-QIV (in immuno subcohort of subjects only);   Solicited local and general symptoms;   Unsolicited adverse events (AEs);   AEs with medically attended visits (MAV);   Serious Adverse events (SAEs);   Potential Immune-Mediated-Diseases (pIMDs)
10 Recruiting Influenza Immunization of Children in India
Condition: Influenza
Interventions: Biological: Inactivated Trivalent Influenza Vaccine (TIV);   Biological: Inactivated poliovirus vaccine (IPV), trivalent
Outcome Measures: Laboratory-confirmed Influenza infection in vaccinated child;   Laboratory-confirmed Influenza infection in household member of a vaccinated child.
11 Recruiting Field Trial of Maternal Influenza Immunization in Asia
Condition: Influenza Human
Interventions: Biological: Influenza vaccine;   Biological: saline placebo
Outcome Measures: Field Trial of Maternal Influenza Immunization;   Substudy #1: Transplacental Transfer of Influenza Antibody from Mother to Infant;   Substudy #2: Indirect Protection of Maternal Influenza Vaccination on Family Members;   Substudy #3: Hepatitis E Infection in Pregnancy;   Pertussis In Infants
12 Not yet recruiting Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: Trivalent virosomal Influenza vaccine;   Biological: Commercial vaccine 1;   Biological: Quadrivalent virosomal Influenza vaccine;   Biological: Commercial vaccine 2
Outcome Measures: Number of participants with Solicited Local Adverse Events (AEs);   Number of participants with Solicited Systemic Adverse Events (AEs);   Number of participants with Unsolicited Adverse Events (AEs);   Number of participants with Serious Adverse Events (SAEs);   Number of Participants with Seroconversion;   Number of Participants with Seroprotection;   Change From Baseline in Geometric Mean Titer (GMT) of HI antibodies
13 Unknown  Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers
Condition: Influenza
Intervention: Behavioral: Influenza vaccination implementation strategy
Outcome Measures: Influenza vaccine uptake among health care workers in the UMCs;   Absenteeism among health care workers during Influenza epidemics;   Patient morbidity and mortality
14 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine (no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
Outcome Measure: To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated)
15 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine(no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
Outcome Measure: To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
16 Unknown  Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
Condition: Influenza
Intervention: Biological: 2012 trivalent Influenza vaccine
Outcome Measures: Immunogenicity;   Safety;   Seasonal Influenza immunogenicity
17 Recruiting Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults
Condition: Influenza
Intervention:
Outcome Measure: Estimate the burden of Influenza disease and Influenza vaccine effectiveness.
18 Recruiting Optimizing Influenza Vaccination in Surgical Oncology Patients
Condition: Influenza
Intervention: Biological: Influenza vaccine
Outcome Measures: Antibody Titer;   Influenza-Like-Illness;   Surgical complications
19 Unknown  Rapid Flu Tests in Travelers With Fever
Condition: Influenza
Interventions: Device: BD Directigen EZ Flu A+B;   Other: Control
Outcome Measure: Difference in utilization of diagnostic tests and anti-infective drugs between the group with rapid flu test and the group without flu test
20 Not yet recruiting Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada
Condition: Influenza
Intervention:
Outcome Measures: Age-adjusted incidence rates of hospitalization and death occurring within 1 month of the diagnosis of Influenza;   Annual incidence rates of Influenza A and B cases;   Annual incidence rates of Influenza A and B cases among certain subsets of the population;   Visits to health care provider within 6 months of the diagnosis of Influenza

These studies may lead to new treatments and are adding insight into Influenza etiology and treatment.

A major focus of Influenza research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Influenza